Vaccine Preventability of Meningococcal Clone, Greater Aachen Region, Germany

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2010 Mar 6

PMID 20202422

Citations 11

Authors

Johannes Elias

Leo M Schouls

Ingrid van de Pol

Wendy C Keijzers

Diana R Martin

Anne Glennie

Philipp Oster

Matthias Frosch

Ulrich Vogel

Arie van der Ende

Affiliations

Soon will be listed here.

Abstract

Emergence of serogroup B meningococci of clonal complex sequence type (ST) 41/44 can cause high levels of disease, as exemplified by a recent epidemic in New Zealand. Multiplication of annual incidence rates (3.1 cases/100,000 population) of meningococcal disease in a defined German region, the city of Aachen and 3 neighboring countries (Greater Aachen) prompted us to investigate and determine the source and nature of this outbreak. Using molecular typing and geographic mapping, we analyzed 1,143 strains belonging to ST41/44 complex, isolated from persons with invasive meningococcal disease over 6 years (2001-2006) from 2 German federal states (total population 26 million) and the Netherlands. A spatially slowly moving clone with multiple-locus variable-number tandem repeat analysis type 19, ST42, and antigenic profile B:P1.7-2,4:F1-5 was responsible for the outbreak. Bactericidal activity in serum samples from the New Zealand MeNZB vaccination campaign confirmed vaccine preventability. Because this globally distributed epidemic strain spreads slowly, vaccination efforts could possibly eliminate meningococcal disease in this area.

Citing Articles

Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017.

Krone M, Gray S, Abad R, Skoczynska A, Stefanelli P, van der Ende A Euro Surveill. 2019; 24(14).

PMID: 30968827 PMC: 6462787. DOI: 10.2807/1560-7917.ES.2019.24.14.1800245.

Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.

Mowlaboccus S, Perkins T, Smith H, Sloots T, Tozer S, Prempeh L PLoS One. 2016; 11(6):e0158315.

PMID: 27355628 PMC: 4927168. DOI: 10.1371/journal.pone.0158315.

Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005.

Wiringa A, Shutt K, Marsh J, Cohn A, Messonnier N, Zansky S PLoS One. 2013; 8(12):e82048.

PMID: 24349182 PMC: 3861328. DOI: 10.1371/journal.pone.0082048.

Genetic characteristics of Neisseria meningitidis serogroup B strains carried by adolescents living in Milan, Italy: implications for vaccine efficacy.

Esposito S, Zampiero A, Terranova L, Montinaro V, Scala A, Ansuini V Hum Vaccin Immunother. 2013; 9(11):2296-303.

PMID: 23880917 PMC: 3981836. DOI: 10.4161/hv.25800.

Consensus recommendation for meningococcal disease prevention in children and adolescents in the Middle East region.

Shibl A, Tufenkeji H, Khalil M, Memish Z J Epidemiol Glob Health. 2013; 2(1):23-30.

PMID: 23856395 PMC: 7320358. DOI: 10.1016/j.jegh.2012.02.002.

References

Urwin R, Russell J, Thompson E, Holmes E, Feavers I, Maiden M . Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun. 2004; 72(10):5955-62. PMC: 517544. DOI: 10.1128/IAI.72.10.5955-5962.2004. View

Martin D, McCallum L, Glennie A, Ruijne N, Blatchford P, OHallahan J . Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine. 2005; 23(17-18):2218-21. DOI: 10.1016/j.vaccine.2005.01.070. View

Yazdankhah S, Kriz P, Tzanakaki G, Kremastinou J, Kalmusova J, Musilek M . Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol. 2004; 42(11):5146-53. PMC: 525265. DOI: 10.1128/JCM.42.11.5146-5153.2004. View

Tully J, Viner R, Coen P, Stuart J, Zambon M, Peckham C . Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006; 332(7539):445-50. PMC: 1382533. DOI: 10.1136/bmj.38725.728472.BE. View

Bille E, Ure R, Gray S, Kaczmarski E, McCarthy N, Nassif X . Association of a bacteriophage with meningococcal disease in young adults. PLoS One. 2008; 3(12):e3885. PMC: 2587699. DOI: 10.1371/journal.pone.0003885. View

Martin D, Walker S, Baker M, Lennon D . New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998; 177(2):497-500. DOI: 10.1086/517385. View

Peltola H, Kataja J, Makela P . Shift in the age-distribution of meningococcal disease as predictor of an epidemic?. Lancet. 1982; 2(8298):595-7. DOI: 10.1016/s0140-6736(82)90669-9. View

Brehony C, Jolley K, Maiden M . Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev. 2006; 31(1):15-26. DOI: 10.1111/j.1574-6976.2006.00056.x. View

Oster P, Lennon D, OHallahan J, Mulholland K, Reid S, Martin D . MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine. 2005; 23(17-18):2191-6. DOI: 10.1016/j.vaccine.2005.01.063. View

10.

Rhee S, Liu T, Holmes S, Shafer R . HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol. 2007; 3(5):e87. PMC: 1866358. DOI: 10.1371/journal.pcbi.0030087. View

11.

Schouls L, van der Ende A, Damen M, van de Pol I . Multiple-locus variable-number tandem repeat analysis of Neisseria meningitidis yields groupings similar to those obtained by multilocus sequence typing. J Clin Microbiol. 2006; 44(4):1509-18. PMC: 1448618. DOI: 10.1128/JCM.44.4.1509-1518.2006. View

12.

Smith J, Smith N, ORourke M, Spratt B . How clonal are bacteria?. Proc Natl Acad Sci U S A. 1993; 90(10):4384-8. PMC: 46515. DOI: 10.1073/pnas.90.10.4384. View

13.

Hunter P, Gaston M . Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J Clin Microbiol. 1988; 26(11):2465-6. PMC: 266921. DOI: 10.1128/jcm.26.11.2465-2466.1988. View

14.

Thompson E, Feavers I, Maiden M . Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology (Reading). 2003; 149(Pt 7):1849-1858. DOI: 10.1099/mic.0.26131-0. View

15.

Maiden M, Bygraves J, Feil E, Morelli G, Russell J, Urwin R . Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A. 1998; 95(6):3140-5. PMC: 19708. DOI: 10.1073/pnas.95.6.3140. View

16.

Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux J . Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ. 1999; 77(6):499-508. PMC: 2557688. View

17.

Bart A, Dankert J, van der Ende A . Representational difference analysis of Neisseria meningitidis identifies sequences that are specific for the hyper-virulent lineage III clone. FEMS Microbiol Lett. 2000; 188(2):111-4. DOI: 10.1111/j.1574-6968.2000.tb09179.x. View

18.

Vermont C, Van Dijken H, de Groot R, van Alphen L, van den Dobbelsteen G . PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children. Vaccine. 2004; 22(23-24):3008-13. DOI: 10.1016/j.vaccine.2004.02.014. View

19.

Van Looveren M, Vandamme P, Hauchecorne M, Wijdooghe M, Carion F, Caugant D . Molecular epidemiology of recent belgian isolates of Neisseria meningitidis serogroup B. J Clin Microbiol. 1998; 36(10):2828-34. PMC: 105072. DOI: 10.1128/JCM.36.10.2828-2834.1998. View

20.

Trotter C, Ramsay M . Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2006; 31(1):101-7. DOI: 10.1111/j.1574-6976.2006.00053.x. View